Your use of the site and services is subject to these policies and terms. Widgets Settings. Search smilingsally's books.
The Gabon Virus
Members with smilingsally's books This information is loading. Loading may take as much as a minute if it hasn't been updated recently. Member connections Friends: wbarker. RSS feeds Recently-added books smilingsally's reviews Reviews of smilingsally's books, not including smilingsally's Helper badges. Most recent activity. Listen by Rene Gutteridge. Comment Wall All comments. Drug Des Devel Ther. Published online Dec Author information Copyright and License information Disclaimer.
This work is published and licensed by Dove Medical Press Limited. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Abstract The unprecedented epidemic spread of chikungunya worldwide illustrates the critical need for potent vaccines and therapeutic interventions.
Introduction Chikungunya is an emerging arthritogenic arboviral illness caused by chikungunya virus CHIKV , a member of the genus Alphavirus in the Togaviridae family. Open in a separate window. Figure 1. Clinical presentation The pathologic mechanism of this virus leads to acute infection of several weeks, which can persist for months with incubation period of 2—12 days. Figure 2. Various strategies projected for chikungunya vaccine development in humans.
VLP CHIKV vaccines In contrast to traditional attenuated and inactivated vaccine approaches, use of VLP has proven to be a new highly efficacious vaccine approach as these are nonreplicating, noninfectious, and self-assembled multiprotein viral constructs resembling native alphavirus. Passive immunization The passive immunization by transfer of purified polyclonal immunoglobulins from human sera has been widely demonstrated in many viral infections. Table 1 Chikungunya vaccine strategies in human clinical trial testing. Summary This review gives an insight about several CHIKV vaccines in clinical pipeline and puts into perspective the findings, merits, and limitations of all clinical trials currently available.
References 1. Epstein PR. Chikungunya fever resurgence and global warming. Am J Trop Med Hyg. Weaver SC, Lecuit M.
Chikungunya virus and the global spread of a mosquito-borne disease. N Engl J Med. J Gen Virol. Vectors of chikungunya virus in Senegal: current data and transmission cycles.
A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog. Chikungunya: a potentially emerging epidemic? East Central South African genotype as the causative agent in reemergence of chikungunya outbreak in India.
Vector Borne Zoonotic Dis. Chikungunya, an epidemic arbovirosis. Lancet Infect Dis. Preparedness for threat of chikungunya in the Pacific. Emerg Infect Dis. Epidemiology of chikungunya in the Americas. J Infect Dis. Chikungunya: epidemiology. Faculty Rev WHO Chikungunya; fact sheet. Chikungunya disease outbreak, Reunion Island. Morrison TE. Reemergence of chikungunya virus. J Virol. Medical Microbiology. Schwartz O, Albert ML. Biology and pathogenesis of chikungunya virus. Nat Rev Microbiol. Clinical features and molecular diagnosis of chikungunya fever from South India.
Clin Infect Dis. Clinical profile of chikungunya patients during the epidemic of in Kerala, India. J Glob Infect Dis.
Chikungunya disease: infection-associated markers from the acute to the chronic phase of arbovirus-induced arthralgia. Chikungunya infection in children. Indian J Pediatr. Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of chikungunya virus. Protective and pathogenic responses to chikungunya virus infection.
Book Review: The Gabon Virus | By The Book
Curr Trop Med Rep. An essential role of antibodies in the control of chikungunya virus infection. J Immunol. Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy. The neutralizing role of IgM during early chikungunya virus infection.
PLoS One. The acute phase of chikungunya virus infection in humans is associated with strong innate immunity and T CD8 cell activation. Current research and clinical trials for a vaccine against chikungunya virus. Vaccine: Develop Ther. Chikungunya vaccines in development. Hum Vaccin Immunother. Powers AM. Vaccine and therapeutic options to control chikungunya virus. Clin Microbiol Rev. Development of an attenuated strain of chikungunya virus for use in vaccine production.
US Military contributions to the global response to pandemic chikungunya. Immunologic interference from sequential administration of live attenuated alphavirus vaccines. Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism.
Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose. Therapeutics and vaccines against chikungunya virus. Attenuated and vectored vaccines protect nonhuman primates against chikungunya virus. JCI Insight. The presence of antibody to chikungunya and other serologically related viruses in the sera of sub-human primate imports to the United States.
Production and evaluation of a formalin-killed chikungunya vaccine. Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus.
Phase-I open label, dose-escalation clinical trial to evaluate the safety, tolerability and immunogenicity of chikungunya vaccine in healthy adults of 18 to 50 years age. A virus-like particle vaccine for epidemic chikungunya virus protects nonhuman primates against infection. Nat Med. Akahata W, Nabel GJ. A specific domain of the chikungunya virus E2 protein regulates particle formation in human cells: implications for alphavirus vaccine design.
Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Production of chikungunya Virus-Like Particles and subunit vaccines in insect cells. Methods Mol Bio. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus. Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial.
Chimpanzee adenoviral vectors as vaccines for outbreak pathogens. Prophylaxis and therapy for chikungunya virus infection. Use of human monoclonal antibodies to treat chikungunya virus infection. A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease. Development of a highly protective combination monoclonal antibody therapy against chikungunya virus. Sci Transl Med. Clayton AM. Monoclonal antibodies as prophylactic and therapeutic agents against chikungunya virus.